Non-antibiotic Small-Molecule Regulation of DHFR-Based Destabilizing Domains In Vivo

Hui Peng, Viet Q. Chau, Wanida Phetsang, Rebecca M. Sebastian, M. Rhia L. Stone, Shyamtanu Datta, Marian Renwick, Yusuf T. Tamer, Erdal Toprak, Andrew Koh, Mark A.T. Blaskovich, John D Hulleman

Research output: Contribution to journalArticle

Abstract

The E. coli dihydrofolate reductase (DHFR) destabilizing domain (DD), which shows promise as a biologic tool and potential gene therapy approach, can be utilized to achieve spatial and temporal control of protein abundance in vivo simply by administration of its stabilizing ligand, the routinely prescribed antibiotic trimethoprim (TMP). However, chronic TMP use drives development of antibiotic resistance (increasing likelihood of subsequent infections) and disrupts the gut microbiota (linked to autoimmune and neurodegenerative diseases), tempering translational excitement of this approach in model systems and for treating human diseases. Herein, we identified a TMP-based, non-antibiotic small molecule, termed 14a (MCC8529), and tested its ability to control multiple DHFR-based reporters and signaling proteins. We found that 14a is non-toxic and can effectively stabilize DHFR DDs expressed in mammalian cells. Furthermore, 14a crosses the blood-retinal barrier and stabilizes DHFR DDs expressed in the mouse eye with kinetics comparable to that of TMP (≤6 h). Surprisingly, 14a stabilized a DHFR DD in the liver significantly better than TMP did, while having no effect on the mouse gut microbiota. Our results suggest that alternative small-molecule DHFR DD stabilizers (such as 14a) may be ideal substitutes for TMP in instances when conditional, non-antibiotic control of protein abundance is desired in the eye and beyond.

Original languageEnglish (US)
Pages (from-to)27-39
Number of pages13
JournalMolecular Therapy - Methods and Clinical Development
Volume15
DOIs
StatePublished - Dec 13 2019

Fingerprint

Tetrahydrofolate Dehydrogenase
Trimethoprim
Blood-Retinal Barrier
Proteins
Microbial Drug Resistance
Neurodegenerative Diseases
Genetic Therapy
Autoimmune Diseases
Escherichia coli
Anti-Bacterial Agents
Ligands
Liver
Infection

Keywords

  • chemical biology
  • conditional regulation
  • destabilizing domain
  • gene therapy
  • hepatic
  • non-antibiotic
  • ocular
  • trimethoprim

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Non-antibiotic Small-Molecule Regulation of DHFR-Based Destabilizing Domains In Vivo. / Peng, Hui; Chau, Viet Q.; Phetsang, Wanida; Sebastian, Rebecca M.; Stone, M. Rhia L.; Datta, Shyamtanu; Renwick, Marian; Tamer, Yusuf T.; Toprak, Erdal; Koh, Andrew; Blaskovich, Mark A.T.; Hulleman, John D.

In: Molecular Therapy - Methods and Clinical Development, Vol. 15, 13.12.2019, p. 27-39.

Research output: Contribution to journalArticle

Peng, Hui ; Chau, Viet Q. ; Phetsang, Wanida ; Sebastian, Rebecca M. ; Stone, M. Rhia L. ; Datta, Shyamtanu ; Renwick, Marian ; Tamer, Yusuf T. ; Toprak, Erdal ; Koh, Andrew ; Blaskovich, Mark A.T. ; Hulleman, John D. / Non-antibiotic Small-Molecule Regulation of DHFR-Based Destabilizing Domains In Vivo. In: Molecular Therapy - Methods and Clinical Development. 2019 ; Vol. 15. pp. 27-39.
@article{dec38e4f760544ae83c4814acb7f1c75,
title = "Non-antibiotic Small-Molecule Regulation of DHFR-Based Destabilizing Domains In Vivo",
abstract = "The E. coli dihydrofolate reductase (DHFR) destabilizing domain (DD), which shows promise as a biologic tool and potential gene therapy approach, can be utilized to achieve spatial and temporal control of protein abundance in vivo simply by administration of its stabilizing ligand, the routinely prescribed antibiotic trimethoprim (TMP). However, chronic TMP use drives development of antibiotic resistance (increasing likelihood of subsequent infections) and disrupts the gut microbiota (linked to autoimmune and neurodegenerative diseases), tempering translational excitement of this approach in model systems and for treating human diseases. Herein, we identified a TMP-based, non-antibiotic small molecule, termed 14a (MCC8529), and tested its ability to control multiple DHFR-based reporters and signaling proteins. We found that 14a is non-toxic and can effectively stabilize DHFR DDs expressed in mammalian cells. Furthermore, 14a crosses the blood-retinal barrier and stabilizes DHFR DDs expressed in the mouse eye with kinetics comparable to that of TMP (≤6 h). Surprisingly, 14a stabilized a DHFR DD in the liver significantly better than TMP did, while having no effect on the mouse gut microbiota. Our results suggest that alternative small-molecule DHFR DD stabilizers (such as 14a) may be ideal substitutes for TMP in instances when conditional, non-antibiotic control of protein abundance is desired in the eye and beyond.",
keywords = "chemical biology, conditional regulation, destabilizing domain, gene therapy, hepatic, non-antibiotic, ocular, trimethoprim",
author = "Hui Peng and Chau, {Viet Q.} and Wanida Phetsang and Sebastian, {Rebecca M.} and Stone, {M. Rhia L.} and Shyamtanu Datta and Marian Renwick and Tamer, {Yusuf T.} and Erdal Toprak and Andrew Koh and Blaskovich, {Mark A.T.} and Hulleman, {John D}",
year = "2019",
month = "12",
day = "13",
doi = "10.1016/j.omtm.2019.08.002",
language = "English (US)",
volume = "15",
pages = "27--39",
journal = "Molecular Therapy - Methods and Clinical Development",
issn = "2329-0501",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Non-antibiotic Small-Molecule Regulation of DHFR-Based Destabilizing Domains In Vivo

AU - Peng, Hui

AU - Chau, Viet Q.

AU - Phetsang, Wanida

AU - Sebastian, Rebecca M.

AU - Stone, M. Rhia L.

AU - Datta, Shyamtanu

AU - Renwick, Marian

AU - Tamer, Yusuf T.

AU - Toprak, Erdal

AU - Koh, Andrew

AU - Blaskovich, Mark A.T.

AU - Hulleman, John D

PY - 2019/12/13

Y1 - 2019/12/13

N2 - The E. coli dihydrofolate reductase (DHFR) destabilizing domain (DD), which shows promise as a biologic tool and potential gene therapy approach, can be utilized to achieve spatial and temporal control of protein abundance in vivo simply by administration of its stabilizing ligand, the routinely prescribed antibiotic trimethoprim (TMP). However, chronic TMP use drives development of antibiotic resistance (increasing likelihood of subsequent infections) and disrupts the gut microbiota (linked to autoimmune and neurodegenerative diseases), tempering translational excitement of this approach in model systems and for treating human diseases. Herein, we identified a TMP-based, non-antibiotic small molecule, termed 14a (MCC8529), and tested its ability to control multiple DHFR-based reporters and signaling proteins. We found that 14a is non-toxic and can effectively stabilize DHFR DDs expressed in mammalian cells. Furthermore, 14a crosses the blood-retinal barrier and stabilizes DHFR DDs expressed in the mouse eye with kinetics comparable to that of TMP (≤6 h). Surprisingly, 14a stabilized a DHFR DD in the liver significantly better than TMP did, while having no effect on the mouse gut microbiota. Our results suggest that alternative small-molecule DHFR DD stabilizers (such as 14a) may be ideal substitutes for TMP in instances when conditional, non-antibiotic control of protein abundance is desired in the eye and beyond.

AB - The E. coli dihydrofolate reductase (DHFR) destabilizing domain (DD), which shows promise as a biologic tool and potential gene therapy approach, can be utilized to achieve spatial and temporal control of protein abundance in vivo simply by administration of its stabilizing ligand, the routinely prescribed antibiotic trimethoprim (TMP). However, chronic TMP use drives development of antibiotic resistance (increasing likelihood of subsequent infections) and disrupts the gut microbiota (linked to autoimmune and neurodegenerative diseases), tempering translational excitement of this approach in model systems and for treating human diseases. Herein, we identified a TMP-based, non-antibiotic small molecule, termed 14a (MCC8529), and tested its ability to control multiple DHFR-based reporters and signaling proteins. We found that 14a is non-toxic and can effectively stabilize DHFR DDs expressed in mammalian cells. Furthermore, 14a crosses the blood-retinal barrier and stabilizes DHFR DDs expressed in the mouse eye with kinetics comparable to that of TMP (≤6 h). Surprisingly, 14a stabilized a DHFR DD in the liver significantly better than TMP did, while having no effect on the mouse gut microbiota. Our results suggest that alternative small-molecule DHFR DD stabilizers (such as 14a) may be ideal substitutes for TMP in instances when conditional, non-antibiotic control of protein abundance is desired in the eye and beyond.

KW - chemical biology

KW - conditional regulation

KW - destabilizing domain

KW - gene therapy

KW - hepatic

KW - non-antibiotic

KW - ocular

KW - trimethoprim

UR - http://www.scopus.com/inward/record.url?scp=85072222413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072222413&partnerID=8YFLogxK

U2 - 10.1016/j.omtm.2019.08.002

DO - 10.1016/j.omtm.2019.08.002

M3 - Article

C2 - 31649953

AN - SCOPUS:85072222413

VL - 15

SP - 27

EP - 39

JO - Molecular Therapy - Methods and Clinical Development

JF - Molecular Therapy - Methods and Clinical Development

SN - 2329-0501

ER -